ATR Inhibition Induces CDK1-SPOP Signaling and Enhances Anti-PD-L1 Cytotoxicity in Prostate Cancer.
Zhe TangPatrick G PiliéChuandong GengGaniraju C ManyamGuang YangSanghee ParkDaoqi WangShan PengCheng WuGuang PengTimothy Anthony YapPaul G CornBradley M BroomTimothy C ThompsonPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)
This work provides a molecular mechanistic rationale for combining ATR-targeted agents with immune checkpoint blockade for patients with CRPC. Multiple early-phase clinical trials of this combination are underway.